生命科學聯合中心/北京大學定量生物學中心

學術報告

題 目:  Using Genomics Approaches to Understand the Function of Oncogenic Fusion Transcription Factors

報告人: Dr. EMILY R. THEISEN

Assistant Professor, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH

Principal Investigator, Center for Childhood Cancer and Blood Diseases,

The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH

時 間: 11月4日（周四）9:00-10:00

地 點: Online (Zoom)

Meeting ID：746 492 6744   Password: 654321

主持人: 齊志研究員

摘 要:

Many pediatric cancers are characterized by the expression of fusion oncogenic transcription factors. These tumors are often aggressive with few effective treatments and poor outcomes for those with metastatic, relapsed, and refractory disease. In the Theisen Lab, we seek to use genomics and proteomics techniques in parallel with molecular and chemical tools to better understand how these fusions function, with a focus on chimeric proteins containing an intrinsically disordered domain from either the EWSR1 or FUS protein. In Ewing sarcoma, we study EWS/FLI and have developed a unique suite of EWS and FLI mutants for functional studies. In the first part of my talk, I’ll discuss how application of new genomics techniques like CUT&RUN and CUT&Tag greatly enhanced our ability to assess the relationship between structure and function of both the EWS and FLI domains. In the second half of my talk, I’ll talk about my groups ongoing efforts to build on these techniques and use Ewing sarcoma as a model system define the enzymatic and nonenzymatic functions of the critical EWS/FLI co-regulator LSD1 and why this data is needed for the intelligent use of LSD1 inhibitors in the clinic

報告人簡介：

Emily Theisen, PhD, is a principal investigator in the Center for Childhood Cancer and Blood Diseases at The Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of pediatrics at The Ohio State University College of Medicine. Dr. Theisen earned her bachelor’s degree in biology from the University of Wisconsin – Madison, and her PhD in pharmaceutics and pharmaceutical chemistry at the University of Utah College of Pharmacy. There she studied in the Center for Investigational Therapeutics at the Huntsman Cancer Institute, focusing on novel epigenetic targeted agents. She then trained with Dr. Stephen Lessnick in the Center for Childhood Cancer & Blood Diseases at Nationwide Children’s as a postdoctoral fellow before joining the faculty. Dr. Theisen has spent her career studying pharmacological modulation of chromatin regulators cancer, with a specific focus in pediatric malignancies.